A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety

Exclusion Criteria

• •Has any clinically significant or known pathogenic genetic variant other than in the SCN2A gene, or a genetic variant that may explain or contribute to the participant's epilepsy and/or developmental disorder.
• •Has bone, spine (eg, kyphosis, scoliosis), bleeding, or other disorder.
• •Has received any experimental or investigational drug, device, or other therapy within 30 days or 5 half-lives (whichever is longer) prior to Screening, including any prior use of gene therapy.
• •Is currently pregnant or breastfeeding or is planning to become pregnant during the clinical trial.